Moderna beats quarterly revenue estimates on COVID vaccine strength

MRNA•2026-07-31

Second-quarter revenue tops estimates

July 31 (Reuters) - Moderna MRNA.O beat Wall Street estimates for second-quarter revenue on Friday benefiting from better-than-expected sales of its COVID-19 vaccine, as the company gears up for the potential launch of its flu shot.

The company reported second-quarter revenue of $145 million, compared with analysts' average estimate of $103 million, according to LSEG data.

Moderna beats quarterly revenue estimates on COVID vaccine strength

Second-quarter revenue tops estimates

Related News

Rtx's Pratt & Whitney Awarded $1.3 Billion F135 Sustainment Contract

Live Markets-How bond vigilantism can hit stocks

Forex-Yen steady as traders remain alert to intervention risks

Producer prices in Brazil fall 0.77% in June

Moleculin's Miracle R/R AML trial reports positive interim data with 37% blinded CRC in venetoclax-failed patients